. Author manuscript; available in PMC: 2013 May 10.

Published in final edited form as: Pharmacotherapy. 2011 Jul;31(7):678–685. doi: 10.1592/phco.31.7.678

Table 3.

Dosing parameters for patients on enoxaparin given every 12 hours whose weight information was available

Parameter	Prophylaxis n=13	Therapeutic^* n=36
Starting LMWH dose (mg) (mean ± SD, range)	39.2 ± 9.5 (30 – 60)	83.0 ± 32.7 (30 – 180)
Ending LMWH dose (mg) (mean ± SD, range)	55.0 ± 22.2 (30 – 100)	85.7 ± 24.7 (30 – 160)
Weight-Based	0.46 ± 0.16	0.90 ± 0.17
Starting LMWH dose (mg/kg) (mean ± SD)
Weight-Based	0.62 ± 0.23	0.87 ± 0.19
Ending LMWH dose (mg/kg) (mean ± SD)	(n=12) ^†	(n=35) ^†
P value for change in dose mg/kg from start to end	P=0.03	P=0.29
Change in LMWH dose (mg/kg) (mean ± SD, range)	0.15 ± 0.22 (−0.2–0.52) (n=12) ^†	−0.01 ± 0.18 (−0.45-0.39) (n=35) ^†
LMWH dose by Trimester of Pregnancy (mg/kg) (mean ± SD)
End of 1^st	0.65 ± 0.01 (n=2)	0.90 ± 0.14 (n=18)
End of 2^nd	0.56 ± 0.15 (n=11)	0.84 ± 0.15 (n=26)
End of 3^rd	0.63 ± 0.24 (n=10)	0.86 ± 0.17 (n=32)

Excluded dalteparin patient, 1 patient with MVR being treated to higher goal levels, and 2 patients whose weights were not known

^†

Weight data missing on 1 patient in each group